Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Denosumab for glucocorticoid-induced osteoporosis

Osteoporotic fractures are one of the principal adverse effects resulting from the therapeutic use of glucocorticoids. These fractures contribute substantially to morbidity in patients who already have major disabling chronic diseases. The prevention of these fractures is, therefore, a high priority in patients who require glucocorticoids, particularly older patients.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. Compston, J. Management of glucocorticoid-induced osteoporosis. Nat. Rev. Rheumatol. 6, 82–88 (2010).

    Article  PubMed  CAS  Google Scholar 

  2. van Staa, T. P., Leufkens, H. G. M. & Cooper, C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos. Int. 13, 777–787 (2002).

    Article  PubMed  Google Scholar 

  3. Reid, D. M. et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J. Bone Miner. Res. 15, 1006–1013 (2000).

    Article  PubMed  CAS  Google Scholar 

  4. Axelsson, K. F., Nilsson, A. G., Wedel, H., Lundh, D. & Lorentzon, M. Association between alendronate use and hip fracture risk in older patients using oral prednisolone. JAMA 318, 146–155 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Saag, K. G. et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 357, 2028–2039 (2007).

    Article  PubMed  CAS  Google Scholar 

  6. Bone, H. G. et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J. Clin. Endocrinol. Metab. 96, 972–980 (2011).

    Article  PubMed  CAS  Google Scholar 

  7. Saag, K. G. et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. (2018).

    PubMed  Article  Google Scholar 

  8. Murad, M. H. et al. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J. Clin. Endocrinol. Metab. 97, 1871–1880 (2012).

    Article  PubMed  CAS  Google Scholar 

  9. Popp, A. W., Zysset, P. K. & Lippuner, K. Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics. Osteoporos Int. 27, 1917–1921 (2016).

    Article  PubMed  CAS  Google Scholar 

  10. Horne, A. M., Mihov, B. & Reid, I. R. Bone loss after romosozumab/denosumab: effects of bisphosphonates. Calcif. Tissue Int. (2018).

    Article  PubMed  Google Scholar 

Download references


I.R.R. receives research funding from the Health Research Council of New Zealand.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Ian R. Reid.

Ethics declarations

Competing interests

The author’s institution has received research funding from Amgen, Merck and Novartis, and the author has received honoraria from these companies and from Eli Lilly.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Reid, I.R. Denosumab for glucocorticoid-induced osteoporosis. Nat Rev Endocrinol 14, 383–384 (2018).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing